[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"benign-prostatic-hyperplasia\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:benign-prostatic-hyperplasia":29},{"pageToken":4,"total":5,"offset":6,"count":7,"results":8},null,71,0,25,[9,46,88,121,153,178,207,228,238,261,280,307,331,355,382,405,425,455,479,510,533,552,577,605,632],{"id":10,"slug":11,"hasResults":12,"nctId":13,"briefTitle":14,"officialTitle":15,"acronym":4,"eligibilityCriteria":16,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":4,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":34,"lastUpdatePostDateStruct":35,"startDateStruct":38,"completionDateStruct":40,"leadSponsor":42,"locationsCount":45},"100053817","sacral-neuromodulation-for-male-overactive-bladder-moab-100053817",false,"NCT06511141","Sacral Neuromodulation for Male Overactive Bladder (MOAB)","Sacral Neuromodulation for Male Overactive Bladder","Key Inclusion Criteria:\n\n1. Participants aged ≥ 18 years at the time of enrollment\n2. Able to complete bladder diaries and patient questionnaires\n3. Primary diagnosis of OAB (urinary urgency incontinence (UUI) or urinary frequency (UF)).\n4. Willing and capable to provide written informed consent and agrees to comply with specified evaluations at clinical investigational sites and attend all follow-up assessments for up to 1 year\n\nKey Exclusion Criteria:\n\n1. Any patient that is not a suitable candidate per investigator discretion\n2. Recent prostate therapy or procedure within the last 6 months at the time of enrollment\n3. Any neurological condition that could interfere with normal bladder function, including stroke, epilepsy, multiple sclerosis, Parkinson's disease, clinically significant peripheral neuropathy, or spinal cord injury (e.g., paraplegia)\n4. Previously implanted with a sacral neuromodulation device, including inactive SNM devices\n5. Any prior treatment with an Implantable Tibial Nerve Stimulation (ITNS)\n6. Positive response to Percutaneous Tibial Nerve Stimulation (PTNS) within the last 3 months at the time of enrollment\n7. Underwent an external trial with any sacral neuromodulation device and was deemed a non-responder by a physician\n8. Any significant medical condition that is likely to interfere with study procedures, device operation, or likely to confound evaluation of study objectives at the discretion of the participating physician.\n9. Uncontrolled diabetes\n10. Known allergic reactions to components of the Axonics SNM System, including titanium, zirconia, polyurethane, epoxy, or silicone","MALE","18 Years",{"count":20,"type":21},150,"ESTIMATED","INTERVENTIONAL",[24],"NA","To assess the post-market clinical outcomes of the Axonics SNM System for treatment of overactive bladder in male patients.",[27,28,29,30,31,32],"Overactive Bladder","Urinary Urgency Incontinence","Benign Prostatic Hyperplasia","Prostate Cancer","Prostatectomy","Urinary Frequency","RECRUITING","2026-07-10",{"date":36,"type":37},"2026-07-13","ACTUAL",{"date":39,"type":37},"2024-10-22",{"date":41,"type":21},"2028-12",{"name":43,"class":44},"Axonics, Inc.","INDUSTRY",21,{"id":47,"slug":48,"hasResults":12,"nctId":49,"briefTitle":50,"officialTitle":51,"acronym":52,"eligibilityCriteria":53,"healthyVolunteers":12,"sex":17,"minAge":54,"maxAge":4,"enrollmentInfo":55,"targetDuration":4,"studyType":57,"phases":4,"briefSummary":58,"conditions":59,"keywords":64,"overallStatus":77,"whyStopped":4,"lastUpdateSubmitDate":78,"lastUpdatePostDateStruct":79,"startDateStruct":80,"completionDateStruct":82,"leadSponsor":84,"locationsCount":87},"100053458","selective-median-lobe-surgery-outcomes-study-100053458","NCT07699718","Selective Median Lobe Surgery Outcomes Study","UNVEIL-BPO Median Lobe Study: An International Multicenter Evaluation of Selective Median Lobe Resection and Enucleation","UNVEIL-BPO","Inclusion Criteria:\n\n* Male patients aged 45 years or older.\n\n  * Moderate-to-severe lower urinary tract symptoms due to benign prostatic obstruction or urinary retention requiring transurethral surgery.\n  * Preoperative findings suggesting median lobe-dominant or median lobe-related obstruction.\n  * Planned selective median lobe-only TURP, HoLEP, or anatomical endoscopic enucleation as part of routine clinical care.\n  * Available baseline International Prostate Symptom Score, uroflowmetry and\u002For postvoid residual volume, prostate volume, intravesical prostatic protrusion measurement, and cystoscopic assessment.\n  * Ability to provide written informed consent and comply with the follow-up schedule.\n\nExclusion Criteria:\n\n* Previous prostate surgery for benign prostatic hyperplasia.\n* Known urethral stricture requiring treatment before or during the index procedure.\n* Known neurogenic lower urinary tract dysfunction.\n* Active prostate cancer or bladder cancer requiring treatment that may confound urinary outcomes.\n* Planned complete TURP, complete HoLEP\u002FAEEP, or lateral lobe-dominant surgery.\n* Severe kissing lateral lobe obstruction considered to require complete surgery rather than selective median lobe surgery.\n* Inability to provide valid baseline or follow-up outcome data.","45 Years",{"count":56,"type":21},420,"OBSERVATIONAL","This prospective multicenter observational cohort study will evaluate clinical outcomes after selective median lobe transurethral surgery for benign prostatic obstruction. Eligible men with lower urinary tract symptoms or urinary retention who are scheduled for selective median lobe-only TURP, HoLEP, or anatomical endoscopic enucleation as part of routine clinical care will be enrolled and followed after surgery.\n\nThe study will collect preoperative clinical data, symptom scores, uroflowmetry, postvoid residual volume, prostate volume, intravesical prostatic protrusion measurements, cystoscopic anatomical findings, intraoperative variables, and postoperative outcomes. The primary outcome is composite clinical failure at 12 months.\n\nThe main aim is to identify practical preoperative urology-based anatomical and functional predictors of clinical failure after selective median lobe surgery and to develop an exploratory prediction model that may help improve patient selection in future practice.",[29,60,61,62,63],"Lower Urinary Tract Symptoms (LUTS) in Men With Benign Prostatic Hyperplasia (BPH)","Benign Prostatic Obstruction","Urinary Retention","Median Lobe Prostatic Enlargement",[65,66,67,68,69,70,71,72,73,74,75,76],"Median lobe","Intravesical prostatic protrusion","Selective median lobe surgery","Selective median lobe enucleation","Selective median lobe resection","TURP","HoLEP","Anatomical endoscopic enucleation of the prostate","Uroflowmetry","Postvoid residual","Clinical failure","Ejaculation preservation","NOT_YET_RECRUITING","2026-07-09",{"date":36,"type":37},{"date":81,"type":21},"2026-09-01",{"date":83,"type":21},"2030-12-01",{"name":85,"class":86},"Necmettin Erbakan University","OTHER",2,{"id":89,"slug":90,"hasResults":12,"nctId":91,"briefTitle":92,"officialTitle":93,"acronym":94,"eligibilityCriteria":95,"healthyVolunteers":12,"sex":17,"minAge":96,"maxAge":4,"enrollmentInfo":97,"targetDuration":4,"studyType":57,"phases":4,"briefSummary":99,"conditions":100,"keywords":101,"overallStatus":77,"whyStopped":4,"lastUpdateSubmitDate":111,"lastUpdatePostDateStruct":112,"startDateStruct":114,"completionDateStruct":116,"leadSponsor":118,"locationsCount":120},"100644381","preoperative-anxiety-and-surgical-fear-in-holmium-laser-enucleation-of-the-prostate-and-transurethral-resection-of-the-prostate-patients-with-benign-prostatic-hyperplasia-100644381","NCT07663097","Preoperative Anxiety and Surgical Fear in Holmium Laser Enucleation of the Prostate and Transurethral Resection of the Prostate Patients With Benign Prostatic Hyperplasia","Evaluation of the Effects of Preoperative Anxiety and Surgical Fear on Postoperative Functional Outcomes and Patient Satisfaction in Patients Scheduled for HoLEP and TURP Due to Benign Prostatic Hyperplasia: A Prospective Observational Study","HoLEP and TURP","Inclusion Criteria:\n\n* Male patients aged 50 years or older\n* Diagnosis of benign prostatic hyperplasia (BPH)\n* Scheduled to undergo HoLEP or TURP\n* Ability to understand and complete study questionnaires\n* Provided written informed consent\n\nExclusion Criteria:\n\n* History of severe psychiatric disorder\n* Active psychiatric treatment\n* Neurogenic bladder or neurologic voiding dysfunction\n* Diagnosis of prostate cancer\n* Previous prostate surgery\n* Inability to comply with study procedures or follow-up visits","50 Years",{"count":98,"type":21},80,"Benign prostatic hyperplasia (BPH) is a common condition in older men and may cause bothersome lower urinary tract symptoms that can negatively affect quality of life. Surgical treatment with Holmium Laser Enucleation of the Prostate (HoLEP) or Transurethral Resection of the Prostate (TURP) is often recommended when medical therapy is insufficient.\n\nThis prospective observational study aims to evaluate whether preoperative anxiety, depression, and surgical fear influence postoperative functional outcomes, urinary continence, erectile function, and patient satisfaction in patients undergoing HoLEP or TURP for BPH. Participants will complete validated psychological and functional questionnaires before surgery and during postoperative follow-up visits at 1 and 3 months. The study will also assess changes in psychological status after surgery and compare outcomes between HoLEP and TURP patients.\n\nThe findings may help improve preoperative patient counseling and identify patients who could benefit from additional psychological support before surgery.",[29],[102,103,70,104,105,106,107,108,109,110],"BPH","HOLEP","Preoperative anxiety","surgical fear","depression","Patient satisfaction","lower urinary tract symptoms","urinary incontinence","erectile function","2026-06-23",{"date":113,"type":37},"2026-06-26",{"date":115,"type":21},"2026-06-14",{"date":117,"type":21},"2027-06-08",{"name":119,"class":86},"Hitit University",1,{"id":122,"slug":123,"hasResults":12,"nctId":124,"briefTitle":125,"officialTitle":126,"acronym":127,"eligibilityCriteria":128,"healthyVolunteers":12,"sex":17,"minAge":129,"maxAge":130,"enrollmentInfo":131,"targetDuration":4,"studyType":22,"phases":133,"briefSummary":134,"conditions":135,"keywords":138,"overallStatus":77,"whyStopped":4,"lastUpdateSubmitDate":144,"lastUpdatePostDateStruct":145,"startDateStruct":147,"completionDateStruct":149,"leadSponsor":151,"locationsCount":120},"100636760","thulium-laser-enucleation-with-bladder-neck-incision-for-small-volume-benign-prostatic-hyperplasia-100636760","NCT07569874","Thulium Laser Enucleation With Bladder Neck Incision for Small-Volume Benign Prostatic Hyperplasia","Thulium Laser Enucleation of the Prostate Combined With Bladder Neck Incision for Small-Volume Benign Prostatic Hyperplasia: A Multicentre, Randomized, Single-Blind, Controlled Trial","ThuLEP-BNI","Inclusion Criteria:\n\n* Male patients aged 40-80 years.\n* Diagnosis of benign prostatic hyperplasia (BPH) and scheduled to undergo surgical treatment.\n* International Prostate Symptom Score (IPSS) of at least 12, maximum urinary flow rate of no more than 15 mL\u002Fs, with a voided volume greater than 150 mL.\n* Prostate volume of less than 30 mL measured by transrectal ultrasound (TRUS), calculated as length × width × height × 0.52.\n* Ability, as assessed by the investigator, to understand the study requirements and complete the scheduled treatment, follow-up visits, and study-related assessments.\n\nExclusion Criteria:\n\n* Inability or refusal to provide written informed consent, or inability to comply with the required follow-up schedule.\n* Prostate-specific antigen (PSA) level of 10 ng\u002FmL or higher, unless prostate cancer has been excluded by biopsy.\n* Confirmed or suspected prostate or bladder malignancy.\n* Pre-existing bladder neck contracture or urethral stricture before surgery.\n* Known coagulation disorder or abnormal coagulation function.\n* Neurogenic bladder or detrusor underactivity that may affect bladder or urethral sphincter function.\n* Benign prostatic hyperplasia (BPH) complicated by acute urinary tract infection, acute prostatitis, or bacterial prostatitis.\n* History of prostate surgery, urethral stricture, or neurogenic bladder.\n* History of prostate cancer or pelvic radiotherapy.\n* Severe cardiovascular disease, pulmonary disease, or other systemic disease that, in the investigator's judgment, would make the patient unable to tolerate surgery.\n* Participation in another clinical trial related to benign prostatic hyperplasia (BPH) within 3 months before enrolment.\n* Any other condition that, in the investigator's opinion, makes the patient unsuitable for participation in this study.","40 Years","80 Years",{"count":132,"type":21},615,[24],"This study will evaluate the safety and effectiveness of thulium laser enucleation of the prostate combined with bladder neck incision in men with small-volume benign prostatic hyperplasia (BPH). Small-volume BPH may still cause significant bladder outlet obstruction and bothersome lower urinary tract symptoms, and the optimal surgical treatment for these patients remains uncertain.\n\nIn this multicenter, randomized, single-blind, controlled trial, 426 eligible men aged 40 to 80 years will be assigned in a 1:1:1 ratio to one of three groups: thulium laser enucleation of the prostate combined with bladder neck incision, thulium laser enucleation alone, or transurethral resection of the prostate. The main goal is to compare the incidence of bladder neck contracture at 6 months after surgery. Other outcomes include symptom improvement, urinary flow, pain score, sexual function, and safety outcomes during follow-up.",[29,136,137],"Bladder Outlet Obstruction","Lower Urinary Tract Symptoms (LUTS)",[139,140,141,142,143],"Small-Volume Benign Prostatic Hyperplasia","Thulium Laser Enucleation of the Prostate","Bladder Neck Incision","Bladder Neck Contracture","Lower Urinary Tract Symptoms","2026-06-16",{"date":146,"type":37},"2026-06-18",{"date":148,"type":21},"2026-07",{"date":150,"type":21},"2028-06",{"name":152,"class":86},"Chinese PLA General Hospital",{"id":154,"slug":155,"hasResults":12,"nctId":156,"briefTitle":157,"officialTitle":158,"acronym":4,"eligibilityCriteria":159,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":160,"targetDuration":4,"studyType":22,"phases":161,"briefSummary":162,"conditions":163,"keywords":166,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":171,"lastUpdatePostDateStruct":172,"startDateStruct":173,"completionDateStruct":175,"leadSponsor":177,"locationsCount":87},"100642494","spinal-versus-general-anesthesia-in-open-simple-prostatectomy-100642494","NCT07643415","Spinal Versus General Anesthesia in Open Simple Prostatectomy","Effect of Spinal Versus General Anesthesia on Postoperative Bleeding in Patients Undergoing Open Simple Prostatectomy: A Prospective Randomized Controlled Trial","Inclusion Criteria:\n\n* Male patients aged 18 years or older.\n* Diagnosis of benign prostatic hyperplasia (BPH).\n* Scheduled to undergo open simple prostatectomy.\n* American Society of Anesthesiologists (ASA) physical status I-III.\n* Ability to provide written informed consent.\n\nExclusion Criteria:\n\n* Refusal or inability to provide informed consent.\n* Patients scheduled for radical prostatectomy due to prostate cancer.\n* Emergency surgery.\n* Known coagulation disorders or clinically significant thrombocytopenia.\n* Ongoing anticoagulant or antiplatelet therapy that cannot be discontinued according to institutional protocols.\n* Contraindication to spinal anesthesia.\n* Participation in another interventional clinical trial that may affect study outcomes.\n* Administration of tranexamic acid or any additional hemostatic agent during the perioperative period.",{"count":98,"type":21},[24],"Open simple prostatectomy is still performed for selected patients with benign prostatic hyperplasia, particularly in cases with large prostate volume. Postoperative bleeding, hematuria, clot retention, and transfusion requirement are clinically important complications after this procedure.\n\nThis prospective randomized controlled trial will compare the effects of spinal anesthesia and general anesthesia on postoperative bleeding in patients undergoing open simple prostatectomy. Participants will be randomized into two groups: spinal anesthesia or general anesthesia. Tranexamic acid or any additional hemostatic agent will not be used. Postoperative bleeding will be assessed using hemoglobin and hematocrit changes, transfusion requirement, hematuria, clot retention, need for bladder irrigation, and bleeding-related reintervention.\n\nThe study aims to determine whether spinal anesthesia is associated with reduced postoperative bleeding compared with general anesthesia in open simple prostatectomy.",[164,29,165],"Urologic Neoplasms","Anesthesia",[167,168,169,170],"Open simple prostatectomy","Spinal anesthesia","general anesthesia","postoperative bleeding","2026-06-15",{"date":144,"type":37},{"date":174,"type":37},"2026-04-29",{"date":176,"type":21},"2026-09-15",{"name":119,"class":86},{"id":179,"slug":180,"hasResults":12,"nctId":181,"briefTitle":182,"officialTitle":183,"acronym":184,"eligibilityCriteria":185,"healthyVolunteers":12,"sex":17,"minAge":96,"maxAge":4,"enrollmentInfo":186,"targetDuration":4,"studyType":22,"phases":188,"briefSummary":190,"conditions":191,"keywords":193,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":198,"lastUpdatePostDateStruct":199,"startDateStruct":201,"completionDateStruct":203,"leadSponsor":205,"locationsCount":120},"100641769","phase-4-tamsulosin-with-or-without-tadalafil-for-trial-without-catheter-after-acute-urinary-retention-due-to-benign-prostatic-hyperplasia-100641769","NCT07654413","Tamsulosin With or Without Tadalafil for Trial Without Catheter After Acute Urinary Retention Due to Benign Prostatic Hyperplasia","Tamsulosin With Versus Without Tadalafil for Trial Without Catheter After Acute Urinary Retention Due to Benign Prostatic Hyperplasia: A Prospective Double-Blind Randomized Trial","TAMS-TAD-TWOC","Inclusion Criteria:\n\n* Male patient aged 50 years or older.\n* First episode of spontaneous painful acute urinary retention.\n* Successful urethral catheterization at presentation.\n* Drained urine volume at presentation of at least 300 mL.\n* Clinical impression of benign prostatic obstruction or benign prostatic hyperplasia based on history, digital rectal examination, and\u002For ultrasound evidence of enlarged prostate.\n* Ability to provide written informed consent.\n\nExclusion Criteria:\n\n* Previous episode of acute urinary retention.\n* Chronic painless urinary retention phenotype.\n* Active urinary tract infection or sepsis.\n* Gross hematuria with clot retention.\n* Suspected or known urethral stricture.\n* Neurogenic bladder or major neurologic disease affecting voiding.\n* History of prostate cancer or bladder cancer.\n* Previous prostate surgery.\n* Current use of nitrates or guanylate cyclase stimulators.\n* Contraindication to tadalafil or tamsulosin.\n* Severe hypotension or unstable cardiovascular disease.\n* Severe renal impairment.\n* Severe hepatic impairment.\n* Current or recent use of phosphodiesterase type 5 inhibitors before enrollment.",{"count":187,"type":21},320,[189],"PHASE4","Acute urinary retention is a common emergency in men with benign prostatic hyperplasia. After bladder drainage with a urethral catheter, patients usually undergo a trial without catheter to determine whether they can pass urine again without recatheterization.\n\nThis study will evaluate whether adding tadalafil 5 mg once daily to tamsulosin 0.4 mg once daily improves the chance of successful trial without catheter in men with first-episode acute urinary retention due to presumed benign prostatic hyperplasia.\n\nParticipants will be randomly assigned to receive either tamsulosin plus tadalafil or tamsulosin plus a matching placebo. Study medication will start within 24 hours after catheterization. The catheter will be removed on Day 7. If the first trial without catheter fails, the catheter will be reinserted and a second rescue trial without catheter will be performed on Day 14.\n\nThe main outcome is overall catheter-free success by Day 14. Participants will also be followed for recurrent urinary retention, post-void residual urine, urinary flow, catheter-related complications, drug-related adverse events, and the need for benign prostatic hyperplasia-related surgery within 3 months.",[192,29,61],"Acute Urinary Retention",[194,195,196,197,29],"Trial Without Catheter","TWOC","Tamsulosin","Tadalafil","2026-06-12",{"date":200,"type":37},"2026-06-17",{"date":202,"type":37},"2026-06-08",{"date":204,"type":21},"2027-12",{"name":206,"class":86},"Beni-Suef University",{"id":208,"slug":209,"hasResults":12,"nctId":210,"briefTitle":211,"officialTitle":212,"acronym":4,"eligibilityCriteria":213,"healthyVolunteers":12,"sex":17,"minAge":96,"maxAge":4,"enrollmentInfo":214,"targetDuration":4,"studyType":22,"phases":216,"briefSummary":217,"conditions":218,"keywords":219,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":222,"lastUpdatePostDateStruct":223,"startDateStruct":224,"completionDateStruct":225,"leadSponsor":227,"locationsCount":120},"100642454","phase-4-tamsulosin-dose-escalation-or-silodosin-switch-before-trial-without-catheter-in-bph-related-acute-urinary-retention-100642454","NCT07650968","Tamsulosin Dose Escalation or Silodosin Switch Before Trial Without Catheter in BPH-Related Acute Urinary Retention","Tamsulosin 0.4 mg Continuation Versus Dose Escalation to 0.8 mg Versus Switch to Silodosin 8 mg for Trial Without Catheter After Acute Urinary Retention Due to Benign Prostatic Hyperplasia: A Randomized Controlled Trial","Inclusion Criteria:\n\n* Male patients aged 50 years or older.\n* Acute urinary retention requiring urethral catheterization.\n* Presumed acute urinary retention secondary to benign prostatic enlargement or benign prostatic obstruction.\n* Already receiving tamsulosin 0.4 mg once daily for at least 4 weeks before the acute urinary retention episode.\n* Successful urethral catheterization at presentation.\n* Initial catheterized urine volume ≤1000 mL, with a clinical presentation consistent with painful acute urinary retention.\n* Prostate enlargement on ultrasound or clinical assessment consistent with benign prostatic hyperplasia or benign prostatic obstruction.\n* Ability to provide written informed consent.\n\nExclusion Criteria:\n\n* Known or suspected prostate cancer.\n* Previous prostate surgery.\n* Previous urethral stricture disease or urethral surgery.\n* Neurogenic bladder or known neurological disease affecting voiding.\n* Chronic urinary retention rather than acute painful retention.\n* Acute urinary retention due to non-BPH causes, including clot retention, bladder stone obstruction, acute prostatitis, urethral trauma, or drug-induced retention.\n* Severe urinary tract infection, sepsis, or fever at presentation.\n* Gross hematuria requiring irrigation.\n* Failed urethral catheterization or need for suprapubic catheterization.\n* Current use of silodosin, alfuzosin, doxazosin, terazosin, tadalafil, anticholinergics, beta-3 agonists, or other drugs that may significantly affect voiding.\n* Severe renal impairment requiring urgent intervention.\n* Symptomatic postural hypotension or recurrent syncope.\n* Known hypersensitivity to silodosin.\n* Severe hepatic impairment.\n* Inability to comply with follow-up.",{"count":215,"type":21},378,[189],"This randomized controlled trial will compare three medication strategies before trial without catheter in men with acute urinary retention due to benign prostatic hyperplasia who were already taking tamsulosin 0.4 mg once daily before the retention episode. After urethral catheterization, eligible participants will be randomly assigned to one of three groups for 7 days: continuation of tamsulosin 0.4 mg once daily, escalation to tamsulosin 0.8 mg once daily, or switching to silodosin 8 mg once daily. The urethral catheter will be removed on Day 7, and the ability to void successfully without re-catheterization will be assessed. Follow-up will continue to Day 30, with additional recording of catheter-free status, recurrent urinary retention, urinary flow, post-void residual urine, symptom scores, adverse drug events, catheter-related complications, and the need for later benign prostatic hyperplasia-related surgery.",[192,29],[194,196,220,221],"Silodosin","Catheter-free status","2026-06-11",{"date":144,"type":37},{"date":202,"type":37},{"date":226,"type":21},"2027-06",{"name":206,"class":86},{"id":229,"slug":4,"hasResults":12,"nctId":13,"briefTitle":14,"officialTitle":15,"acronym":4,"eligibilityCriteria":16,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":230,"targetDuration":4,"studyType":22,"phases":231,"briefSummary":25,"conditions":232,"keywords":4,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":222,"lastUpdatePostDateStruct":233,"startDateStruct":234,"completionDateStruct":235,"leadSponsor":236,"locationsCount":237},"100555365",{"count":20,"type":21},[24],[27,28,29,30,31,32],{"date":171,"type":37},{"date":39,"type":37},{"date":41,"type":21},{"name":43,"class":44},20,{"id":239,"slug":240,"hasResults":12,"nctId":241,"briefTitle":242,"officialTitle":243,"acronym":244,"eligibilityCriteria":245,"healthyVolunteers":12,"sex":17,"minAge":96,"maxAge":4,"enrollmentInfo":246,"targetDuration":4,"studyType":22,"phases":248,"briefSummary":249,"conditions":250,"keywords":252,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":256,"lastUpdatePostDateStruct":257,"startDateStruct":258,"completionDateStruct":259,"leadSponsor":260,"locationsCount":120},"100642693","water-vapor-thermal-therapy-versus-ejaculation-sparing-bipolar-transurethral-enucleation-for-benign-prostatic-hyperplasia-100642693","NCT07648888","Water Vapor Thermal Therapy Versus Ejaculation-Sparing Bipolar Transurethral Enucleation for Benign Prostatic Hyperplasia","Water Vapor Thermal Therapy Versus Ejaculation-Sparing Bipolar Transurethral Enucleation of the Prostate for Benign Prostatic Hyperplasia: A Prospective Comparative Study","REZ-ESBTUEP","Inclusion Criteria:\n\n* Male patients aged 50 years or older.\n* Symptomatic benign prostatic hyperplasia with moderate-to-severe lower urinary tract symptoms.\n* International Prostate Symptom Score (IPSS) 13 or higher.\n* Prostate volume 30 to 80 mL measured by transrectal ultrasound.\n* Maximum urinary flow rate (Qmax) 15 mL\u002Fs or less with voided volume 150 mL or more.\n* Post-void residual urine volume 250 mL or less.\n* Failed, intolerant, or unwilling to continue medical therapy for benign prostatic hyperplasia.\n* Sexually active within the previous 3 months.\n* Preserved antegrade ejaculation at baseline.\n* Patient wishes to preserve ejaculation.\n* Ability to complete the International Prostate Symptom Score (IPSS), International Index of Erectile Function-5 (IIEF-5), and Male Sexual Health Questionnaire-Ejaculatory Dysfunction Short Form (MSHQ-EjD-SF).\n* Written informed consent.\n\nExclusion Criteria:\n\n* Suspected or confirmed prostate cancer.\n* Abnormal prostate-specific antigen or digital rectal examination suspicious for malignancy unless prostate cancer has been excluded according to standard clinical practice.\n* Previous prostate surgery.\n* Previous urethral surgery likely to affect instrumentation or study outcomes.\n* Urethral stricture disease.\n* Neurogenic bladder dysfunction.\n* Active urinary tract infection until adequately treated.\n* Bladder stones requiring concomitant surgery.\n* Prostate volume less than 30 mL or more than 80 mL.\n* Baseline anejaculation or severe ejaculatory dysfunction.\n* No sexual activity during the previous 3 months.\n* Chronic indwelling urethral or suprapubic catheter.\n* Recurrent urinary retention or suspected detrusor underactivity requiring urodynamic clarification.\n* Post-void residual urine volume more than 250 mL.\n* Uncontrolled coagulopathy.\n* Anticoagulation or antiplatelet therapy that cannot be safely managed perioperatively.\n* Unfitness for anesthesia or intervention.\n* Inability or unwillingness to comply with follow-up.",{"count":247,"type":21},120,[24],"This prospective comparative study will evaluate Water Vapor Thermal Therapy (WVTT\u002FRezum) versus Ejaculation-Sparing Bipolar Transurethral Enucleation of the Prostate (ES-B-TUEP) in sexually active men with symptomatic benign prostatic hyperplasia.\n\nEligible patients will have moderate-to-severe lower urinary tract symptoms, preserved antegrade ejaculation at baseline, and will be candidates for procedural treatment after failure, intolerance, or unwillingness to continue medical therapy. This is not a randomized study. Treatment selection will be based on shared decision-making between the patient and the treating surgeon after standardized counseling about both procedures.\n\nThe study will compare ejaculatory function, urinary symptom improvement, urinary flow, post-void residual urine, erectile function, perioperative outcomes, complications, catheterization duration, hospital stay, medication restart, and retreatment or reintervention during follow-up. The primary outcome will be the change in the Male Sexual Health Questionnaire-Ejaculatory Dysfunction Short Form Function domain score from baseline to 12 months.",[29,143,251],"Ejaculatory Dysfunction",[253,254,255],"Water Vapor Thermal Therapy","Ejaculation-Sparing","MSHQ-EjD-SF","2026-06-10",{"date":171,"type":37},{"date":202,"type":37},{"date":204,"type":21},{"name":206,"class":86},{"id":262,"slug":263,"hasResults":12,"nctId":264,"briefTitle":265,"officialTitle":266,"acronym":4,"eligibilityCriteria":267,"healthyVolunteers":12,"sex":17,"minAge":96,"maxAge":4,"enrollmentInfo":268,"targetDuration":4,"studyType":22,"phases":269,"briefSummary":270,"conditions":271,"keywords":272,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":256,"lastUpdatePostDateStruct":276,"startDateStruct":277,"completionDateStruct":278,"leadSponsor":279,"locationsCount":120},"100641924","water-vapor-thermal-therapy-versus-ejaculation-preserving-holep-for-benign-prostatic-hyperplasia-100641924","NCT07648875","Water Vapor Thermal Therapy Versus Ejaculation-Preserving HoLEP for Benign Prostatic Hyperplasia","Water Vapor Thermal Therapy Versus Ejaculation-Preserving Holmium Laser Enucleation of the Prostate for Benign Prostatic Hyperplasia: A Prospective Comparative Study","Inclusion Criteria:\n\n* Male patients aged 50 years or older.\n* Symptomatic benign prostatic hyperplasia with moderate-to-severe lower urinary tract symptoms.\n* International Prostate Symptom Score (IPSS) of 13 or higher.\n* Prostate volume 30 to 80 mL measured by transrectal ultrasound.\n* Maximum urinary flow rate (Qmax) of 15 mL\u002Fs or less with voided volume of at least 150 mL.\n* Post-void residual urine volume of 250 mL or less.\n* Failure, intolerance, or unwillingness to continue medical therapy for benign prostatic hyperplasia.\n* Sexually active within the previous 3 months.\n* Preserved antegrade ejaculation at baseline.\n* Patient wishes to preserve ejaculation.\n* Ability to complete the International Prostate Symptom Score (IPSS), International Index of Erectile Function-5 (IIEF-5), and Male Sexual Health Questionnaire-Ejaculatory Dysfunction-Short Form (MSHQ-EjD-SF).\n* Written informed consent.\n\nExclusion Criteria:\n\n* Suspected or confirmed prostate cancer.\n* Abnormal prostate-specific antigen or digital rectal examination suspicious for malignancy unless prostate cancer has been excluded according to standard clinical practice.\n* Previous prostate surgery.\n* Previous urethral surgery likely to affect instrumentation or study outcomes.\n* Urethral stricture disease.\n* Neurogenic bladder dysfunction.\n* Active urinary tract infection until adequately treated.\n* Bladder stones requiring concomitant surgery.\n* Prostate volume less than 30 mL or more than 80 mL.\n* Baseline anejaculation or severe ejaculatory dysfunction.\n* No sexual activity during the previous 3 months.\n* Chronic indwelling urethral or suprapubic catheter.\n* Suspected detrusor underactivity requiring urodynamic clarification.\n* Post-void residual urine volume more than 250 mL.\n* Uncontrolled coagulopathy.\n* Anticoagulation or antiplatelet therapy that cannot be safely managed perioperatively.\n* Unfitness for anesthesia or intervention.\n* Inability or unwillingness to comply with follow-up.",{"count":247,"type":21},[24],"This prospective comparative study will evaluate Water Vapor Thermal Therapy (Rezum) versus ejaculation-preserving Holmium Laser Enucleation of the Prostate (EP-HoLEP) in sexually active men with symptomatic benign prostatic hyperplasia and prostate volume 30-80 mL.\n\nEligible patients will not be randomized. The treatment option will be selected through shared decision-making between the patient and treating physician after standardized counseling about the expected benefits, risks, recovery, catheter duration, urinary outcomes, durability, and potential effects on ejaculation and sexual function.\n\nThe main objective is to compare the change in ejaculatory function from baseline to 12 months using the Male Sexual Health Questionnaire-Ejaculatory Dysfunction-Short Form (MSHQ-EjD-SF) Function domain. Secondary outcomes will include urinary symptom improvement, quality of life, maximum urinary flow rate, post-void residual urine volume, erectile function, antegrade ejaculation preservation, catheterization duration, hospital stay, complications, restart of benign prostatic hyperplasia medication, and retreatment or reintervention within 12 months.",[29,143],[253,273,274,275],"Rezum","Ejaculation-Preserving HoLEP","Male Sexual Health Questionnaire",{"date":171,"type":37},{"date":202,"type":37},{"date":204,"type":21},{"name":206,"class":86},{"id":281,"slug":282,"hasResults":12,"nctId":283,"briefTitle":284,"officialTitle":285,"acronym":286,"eligibilityCriteria":287,"healthyVolunteers":12,"sex":17,"minAge":54,"maxAge":4,"enrollmentInfo":288,"targetDuration":4,"studyType":22,"phases":290,"briefSummary":291,"conditions":292,"keywords":293,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":300,"lastUpdatePostDateStruct":301,"startDateStruct":302,"completionDateStruct":304,"leadSponsor":306,"locationsCount":237},"100581357","a-clinical-study-to-evaluate-the-safety-and-efficacy-of-the-flostent-in-men-with-benign-prostatic-hyperplasia-symptoms-100581357","NCT06849258","A Clinical Study to Evaluate the Safety and Efficacy of the FloStent in Men With Benign Prostatic Hyperplasia Symptoms","A Prospective, Multicenter, Double Blind, Randomized, Clinical Study to Evaluate the Safety and Efficacy of The FloStent in Men Suffering From Benign Prostatic Hyperplasia Symptoms","RAPID-III","Inclusion Criteria:\n\n* Male subjects \\> 45 years of age who have symptomatic BPH\n* International Prostate Symptom Score (IPSS) score \\>13\n* Peak urinary flow rate (Qmax): \\>5 mL\u002Fsec and \\\u003C13 mL\u002Fsec with minimum voided volume of \\>125 mL\n* Post-void residual (PVR) \\\u003C250 mL\n* Prostate volume 25 to 80 mL\n* Prostatic urethral length 20-50 mm\n* Able to complete the study protocol and visits\n\nExclusion Criteria:\n\n* Presence of an artificial urinary sphincter or stent(s) in the urethra or prostate\n* Prior minimally invasive intervention or surgical intervention of the prostate or urethra\n* PSA \\>10 ng\u002FmL\n* Bladder cancer or bladder stones\n* Active urinary tract infection (UTI)\n* Uncontrolled diabetes\n* Part of a vulnerable population (cognitively challenged or are incarcerated)",{"count":289,"type":21},215,[24],"The goal of this study is to determine the safety and effectiveness of the FloStent, a medical device used to treat men with symptoms of Benign Prostatic Hyperplasia, compared to sham (procedure without deployment of the FloStent). All participants will undergo a flexible cystoscopy and those randomized to the treatment arm will receive the FloStent, while those randomized to the sham arm will not receive the FloStent.",[29],[294,295,296,102,297,298,299],"benign prostatic hyperplasia","FloStent","Rivermark Medical","LUTS","Lower urinary tract symptoms","enlarged prostate","2026-06-09",{"date":222,"type":37},{"date":303,"type":37},"2025-02-10",{"date":305,"type":21},"2032-12-31",{"name":296,"class":44},{"id":308,"slug":309,"hasResults":12,"nctId":310,"briefTitle":311,"officialTitle":312,"acronym":4,"eligibilityCriteria":313,"healthyVolunteers":314,"sex":17,"minAge":18,"maxAge":315,"enrollmentInfo":316,"targetDuration":4,"studyType":22,"phases":318,"briefSummary":319,"conditions":320,"keywords":322,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":324,"lastUpdatePostDateStruct":325,"startDateStruct":326,"completionDateStruct":328,"leadSponsor":329,"locationsCount":120},"100643473","moses-20-vs-magneto-for-holep---a-randomized-controlled-trial-100643473","NCT07632742","Moses 2.0 vs Magneto for HoLEP - a Randomized Controlled Trial","MOSES 2.0 vs Quanta Magneto 150 Holmium Laser for Holmium Laser Enucleation of the prostate-a Randomized Controlled Trial","Inclusion Criteria:\n\n* Undergoing HoLEP for the treatment of bothersome lower urinary tract symptoms\n* Internet access and a device to complete postoperative questionnaires (smartphone, tablet, laptop or desktop computer)\n\nExclusion Criteria:\n\n* Patients who lack decisional capacity\n* Patients unable to read\u002Fspeak English\n* Patients who are on a blood thinner (anticoagulation medication)\n* Patients who do not have internet access to complete postoperative surveys",true,"100 Years",{"count":317,"type":21},180,[24],"The objective of this study is to compare the Magneto 150 holmium laser to the current MOSES 2.0 technology to see if there is a benefit in decreased hemostasis time intraoperatively.",[321,29],"Enlarged Prostate (BPH)",[71,323],"Holmium laser","2026-06-05",{"date":202,"type":37},{"date":327,"type":21},"2026-06",{"date":150,"type":21},{"name":330,"class":86},"Northwestern University",{"id":332,"slug":333,"hasResults":12,"nctId":334,"briefTitle":335,"officialTitle":336,"acronym":337,"eligibilityCriteria":338,"healthyVolunteers":12,"sex":17,"minAge":96,"maxAge":4,"enrollmentInfo":339,"targetDuration":4,"studyType":22,"phases":341,"briefSummary":342,"conditions":343,"keywords":344,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":348,"lastUpdatePostDateStruct":349,"startDateStruct":350,"completionDateStruct":352,"leadSponsor":354,"locationsCount":120},"100640142","ejaculation-preserving-versus-standard-bipolar-tuep-for-bph-100640142","NCT07629479","Ejaculation-Preserving Versus Standard Bipolar TUEP for BPH","Bipolar Transurethral Enucleation of the Prostate With Preservation of Ejaculation in Patients With Benign Prostatic Hyperplasia: A Randomized Controlled Trial","EP-BTUEP","Inclusion Criteria:\n\n* Male patients with lower urinary tract symptoms secondary to benign prostatic obstruction after failed medical treatment for at least 3 months.\n* Sexually active patients with a continuous relationship with the same partner.\n* International Prostate Symptom Score of 8 or greater.\n* Transrectal ultrasound-estimated prostate size between 40 and 100 cc.\n* Eligible for bipolar transurethral enucleation of the prostate.\n* Ability to complete the required sexual and urinary function questionnaires.\n* Ability to provide written informed consent.\n\nExclusion Criteria:\n\n* Preoperative sexual dysfunction.\n* Preoperative ejaculatory dysfunction.\n* Diagnosis or suspicion of prostate cancer.\n* Neurological disorders affecting lower urinary tract or sexual function.\n* Detrusor hypocontractility.\n* Catheter-dependent patients.\n* Patients with bladder stones.\n* Inability or refusal to provide informed consent.",{"count":340,"type":21},60,[24],"This prospective randomized controlled trial will compare ejaculation-preserving bipolar transurethral enucleation of the prostate with standard bipolar transurethral enucleation of the prostate in sexually active men with benign prostatic hyperplasia and lower urinary tract symptoms after failed medical treatment. Participants will be randomly assigned to either ejaculation-preserving B-TUEP or standard B-TUEP. The study will evaluate preservation of ejaculatory function, erectile function, urinary symptom improvement, uroflowmetry outcomes, post-void residual urine, perioperative complications, and need for retreatment during follow-up.",[29,143,61],[345,346,76,347],"Bipolar transurethral enucleation of the prostate","B-TUEP","International Prostate Symptom Score","2026-06-01",{"date":324,"type":37},{"date":351,"type":37},"2025-09-08",{"date":353,"type":21},"2026-09",{"name":206,"class":86},{"id":356,"slug":357,"hasResults":12,"nctId":358,"briefTitle":359,"officialTitle":360,"acronym":4,"eligibilityCriteria":361,"healthyVolunteers":12,"sex":17,"minAge":362,"maxAge":4,"enrollmentInfo":363,"targetDuration":4,"studyType":57,"phases":4,"briefSummary":365,"conditions":366,"keywords":367,"overallStatus":77,"whyStopped":4,"lastUpdateSubmitDate":374,"lastUpdatePostDateStruct":375,"startDateStruct":376,"completionDateStruct":378,"leadSponsor":380,"locationsCount":4},"100637278","a-study-to-track-the-safety-of-vesomni-in-men-in-south-korea-treated-in-routine-clinical-practice-for-the-urinary-symptoms-of-benign-prostatic-hyperplasia-enlarged-prostate-100637278","NCT07619105","A Study to Track the Safety of Vesomni in Men in South Korea Treated in Routine Clinical Practice for the Urinary Symptoms of Benign Prostatic Hyperplasia (Enlarged Prostate)","Post-marketing Observational Study for Vesomni Modified Release Tablet 6 mg\u002F0.4 mg (Solifenacin Succinate\u002FTamsulosin Hydrochloride) in Male Patients With Moderate to Severe Storage Symptoms and Voiding Symptoms Associated With BPH Who Are Not Adequately Responding to Treatment With Tamsulosin Monotherapy in South Korea","Inclusion Criteria:\n\n* A patient (adult male) who receives treatment with Vesomni, according to the approved local label during the registration period.\n\nExclusion Criteria:\n\n* A patient with any contraindication for Vesomni, according to the approved local label.\n* A patient who enrolled or is planning to enroll in any study of an investigational medicine during the observation period.","19 Years",{"count":364,"type":21},600,"Benign prostatic hyperplasia (BPH), also known as an enlarged prostate, happens more often in men as they age. This condition causes a sudden need to pass urine, which is hard to control. Men with an enlarged prostate may need to pass urine many times during the day and night which can affect their wellbeing. There are treatments available, like tamsulosin but they don't work well in some men and can cause further health problems. Vesomni is approved in South Korea to treat urinary symptoms in men with an enlarged prostate, when treatment with tamsulosin doesn't work well enough.\n\nThis study will track the safety of Vesomni given to men in South Korea who have moderate to severe symptoms from an enlarged prostate, who have previously been treated with tamsulosin and found it didn't work well. The safety of Vesomni is tracked by mainly collecting information from their medical records. The sponsor will ask for extra information to be collected, and if any health problems were caused by Vesomni. In this study, researchers want to learn about the safety of Vesomni and how well it controls symptoms in men with an enlarged prostate.\n\nThe men's own doctor decides on treatment, as part of routine clinical practice, not the sponsor (Astellas). This study is about collecting information only. Most information about the safety and control of symptoms will be collected from medical records. The sponsor will also ask for extra information to be collected. All information will be collected for up to 24 weeks after the men start treatment with Vesomni.",[29],[368,369,370,371,372,373],"Pollakiuria","Micturition urgency","Voiding Symptoms","Vesomni","Solifenacin succinate","Tamsulosin hydrochloride","2026-05-26",{"date":348,"type":37},{"date":377,"type":21},"2026-06-30",{"date":379,"type":21},"2030-11-30",{"name":381,"class":44},"Astellas Pharma Korea, Inc.",{"id":383,"slug":384,"hasResults":12,"nctId":385,"briefTitle":386,"officialTitle":387,"acronym":4,"eligibilityCriteria":388,"healthyVolunteers":12,"sex":17,"minAge":96,"maxAge":4,"enrollmentInfo":389,"targetDuration":4,"studyType":22,"phases":390,"briefSummary":391,"conditions":392,"keywords":393,"overallStatus":77,"whyStopped":4,"lastUpdateSubmitDate":396,"lastUpdatePostDateStruct":397,"startDateStruct":399,"completionDateStruct":401,"leadSponsor":403,"locationsCount":4},"100638203","comparative-outcomes-of-rezm-versus-echolaser-for-treatment-of-benign-prostatic-hyperplasia-with-enlarged-median-lobe-100638203","NCT07578428","Comparative Outcomes of Rezūm Versus EchoLaser for Treatment of Benign Prostatic Hyperplasia With Enlarged Median Lobe.","Comparative Outcomes of Rezūm (Water Vapor Therapy) Versus EchoLaser (Transperineal Laser Ablation) for Treatment of Benign Prostatic Hyperplasia With Enlarged Median Lobe. A Prospective Randomized Comparative Study.","Inclusion Criteria:\n\nInclusion Criteria:\n\nMale patients aged 50 years or older.\n\nDiagnosis of symptomatic BPH with moderate-to-severe lower urinary tract symptoms, defined as an IPSS ≥ 12.\n\nTotal prostate volume between 30 mL and 80 mL, confirmed via Transrectal Ultrasound (TRUS) or mpMRI.\n\nPresence of an enlarged, obstructing intravesical median lobe visualized via imaging or baseline cystoscopy.\n\nPeak urinary flow rate (Qmax) between 5 and 15 mL\u002Fs with a minimum voided volume of ≥ 125 mL.\n\nExclusion Criteria:\n\nConfirmed or suspected prostate cancer (e.g., PSA \\> 4.0 ng\u002FmL without a subsequent negative prostate biopsy or MRI).\n\nHistory of prior surgical interventions for BPH (e.g., TURP, HOLEP, or other MISTs).\n\nPresence of urethral strictures, bladder neck contracture, or established neurogenic bladder dysfunction.\n\nActive urinary tract infection (UTI) or an episode of acute urinary retention requiring an indwelling catheter at the time of screening.\n\nPrevious pelvic radiation therapy or severe pelvic trauma.\n\nInability to safely pause anticoagulant\u002Fantiplatelet therapy per standard hospital perioperative protocols, if applicable.",{"count":98,"type":21},[24],"This study evaluates and compares two minimally invasive surgical therapies for treating men with benign prostatic hyperplasia (BPH) who specifically have an enlarged median lobe. The two treatments being compared are Rezūm (water vapor thermal therapy) and EchoLaser (transperineal laser ablation). Participants will be randomized into two equal groups to receive either the Rezūm treatment or the EchoLaser treatment. The primary goal of the study is to evaluate the change in urinary symptoms over a 6-month period using the International Prostate Symptom Score (IPSS). The study will also assess how well each treatment improves urine flow, reduces the size of the prostate, preserves sexual function, and minimizes complications.",[29],[394,395],"Rezūm","EchoLaser","2026-05-05",{"date":398,"type":37},"2026-05-11",{"date":400,"type":21},"2026-05-01",{"date":402,"type":21},"2027-05-01",{"name":404,"class":86},"Benha University",{"id":406,"slug":407,"hasResults":12,"nctId":408,"briefTitle":409,"officialTitle":410,"acronym":4,"eligibilityCriteria":411,"healthyVolunteers":314,"sex":17,"minAge":96,"maxAge":130,"enrollmentInfo":412,"targetDuration":4,"studyType":22,"phases":414,"briefSummary":415,"conditions":416,"keywords":418,"overallStatus":77,"whyStopped":4,"lastUpdateSubmitDate":396,"lastUpdatePostDateStruct":420,"startDateStruct":422,"completionDateStruct":423,"leadSponsor":424,"locationsCount":120},"100637217","emsella-for-reducing-tsui-after-holep-100637217","NCT07580404","Emsella for Reducing tSUI After HOLEP","The Utility of Emsella for Reducing Transient Stress Urinary Incontinence (tSUI) Following Holmium Laser Enucleation of the Prostate (HoLEP)","Inclusion Criteria:\n\n* Prostate sizing 80-150g\n* Ability to independently transfer and tolerate all 30min Emsella treatments (e.g. not wheelchair bound, no mobility issues)\n* Baseline M-ISI scores \\\u003C4\n* Same-day catheter removal and discharge\n* Able to read, understand, and complete surveys and questionnaires\n\nExclusion Criteria:\n\n* Catheter dependence\n* Previous BPH procedure\n* Previous pelvic surgeries\n* Pre-existing pelvic floor dysfunction\n* Neurogenic bladder\n* Overactive bladder - e.g. prescribed and taking any oxybutynin or mirabegron\n* Preoperative pad-use for incontinence",{"count":413,"type":21},30,[24],"This study aims to investigate the effectiveness of the Emsella chair treatments at different timepoints. Before and after the holmium laser enucleation of the prostate (HoLEP).",[29,417,321],"Enlarged Prostate With Lower Urinary Tract Symptoms",[71,419],"Emsella",{"date":421,"type":37},"2026-05-12",{"date":327,"type":21},{"date":150,"type":21},{"name":330,"class":86},{"id":426,"slug":427,"hasResults":12,"nctId":428,"briefTitle":429,"officialTitle":430,"acronym":4,"eligibilityCriteria":431,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":432,"targetDuration":4,"studyType":22,"phases":434,"briefSummary":435,"conditions":436,"keywords":439,"overallStatus":77,"whyStopped":4,"lastUpdateSubmitDate":447,"lastUpdatePostDateStruct":448,"startDateStruct":450,"completionDateStruct":451,"leadSponsor":453,"locationsCount":120},"100635459","feasibility-and-utility-of-a-prehabilitation-program-for-use-in-patients-with-benign-prostatic-hyperplasia-who-have-elected-to-undergo-holmium-laser-enucleation-of-the-prostate-holep-100635459","NCT07552961","Feasibility and Utility of a Prehabilitation Program for Use in Patients With Benign Prostatic Hyperplasia Who Have Elected to Undergo Holmium Laser Enucleation of the Prostate (HoLEP).","Evaluating the Feasibility of a Comprehensive Prehabilitation Program for Use in Benign Prostatic Hyperplasia Patients Undergoing Holmium Laser Enucleation of the Prostate","Inclusion Criteria:\n\n1. Opting to undergo HoLEP procedure for the treatment of BPH\n2. Estimated prostate size (\\>60 ml)\n3. Have received permission to exercise from their primary care provider\n4. Access to a computer\u002F smartphone and internet access to complete associated questionnaires and access online educational resource\n\nExclusion Criteria:\n\n1\\. Other medical or psychiatric conditions which preclude the ability to participate in exercise or utilize the online education module",{"count":433,"type":21},40,[24],"Benign prostatic hyperplasia (BPH) is a debilitating condition which is highly prevalent in older males, up to 45% of those over the age of 45 are affected and 80% of those over the age of 70 are affected. While not all men with BPH experience problematic symptoms, many will experience lower urinary tract symptoms (LUTS) including difficulty passing urine, recurrent urinary tract infections, bladder stones, and hematuria. Holmium Laser Enucleation of the Prostate (HoLEP) is the gold standard in terms of surgical BPH management and is associated with a low risk for requiring repeat interventions. However, in the weeks following HoLEP procedures many men will experience transient urinary incontinence which can be distressing to patients.\n\nIn the setting of prostate cancer, exercise and mental health supports prior to surgery has been shown to improve incontinence and post-surgical recovery. This is often termed prehabilitation and consists of programming done in the months before surgery. The objective of this study is to assess the safety and feasibility of prehabilitation programming prior to HoLEP procedures for men with BPH.\n\nThe investigators will be randomizing 40 patients into 2 groups, one receiving standard of care interventions prior to their HoLEP surgery and one receiving at least 12 weeks of comprehensive prehabilitation programming including: pelvic floor physiotherapy, access to additional informational resources, and access to mental health supports including individual and couples counselling. In both groups the investigators will be collecting key demographics and clinical information from patients as well as assessing their urinary function through several questionnaires before prehabilitation, immediately before surgery, and up to 1 year after surgery.\n\nThe investigators hope to establish that prehabilitation is a safe and feasible option for these patients. Secondarily investigators hope to provide evidence that prehabilitation improves incontinence faster following HoLEP procedures and improves post-surgical recovery.",[29,437,438],"Benign Prostatic Hyperplasia With Lower Urinary Tract Symptoms","Benign Prostatic Hyperplasia With Outflow Obstruction",[440,441,442,443,444,445,446],"Prehabilitation","Exercise Therapy","Holmium Laser Enucleation of the Prostate","Mental Health Support","Safety","Feasibility","Incontinence","2026-04-22",{"date":449,"type":37},"2026-04-27",{"date":348,"type":21},{"date":452,"type":21},"2027-11-01",{"name":454,"class":86},"University of Calgary",{"id":456,"slug":457,"hasResults":12,"nctId":458,"briefTitle":459,"officialTitle":460,"acronym":4,"eligibilityCriteria":461,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":462,"targetDuration":464,"studyType":57,"phases":4,"briefSummary":465,"conditions":466,"keywords":467,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":469,"lastUpdatePostDateStruct":470,"startDateStruct":472,"completionDateStruct":474,"leadSponsor":476,"locationsCount":478},"100480992","bph-global-registry-100480992","NCT05543200","BPH Global Registry","A Global Registry of Treatments and Outcomes for Benign Prostatic Hyperplasia","Inclusion Criteria:\n\n* Primary diagnosis of BPH with LUTS with prescribed medical treatment or surgical intervention\n\nExclusion Criteria:\n\n* Non-symptomatic BPH\n* No treatment prescribed for BPH",{"count":463,"type":21},7500,"3 Years","Benign prostatic hyperplasia (BPH) is one of the most common performed surgical procedures in urology. Over the past few decades there have been an increasing development of newer surgical treatment options. Additionally, the outcome parameters for BPH treatments have been standardized. While data are available for the initial pivotal studies, post-market release data are lacking. Under the umbrella of uCARE, we have started a prospective, ongoing international registry for recording demographics and outcomes for patients undergoing surgical treatments for BPH.",[29,143],[468],"BPH, Registry, LUTS","2026-04-21",{"date":471,"type":37},"2026-04-24",{"date":473,"type":37},"2023-03-13",{"date":475,"type":21},"2027-03",{"name":477,"class":86},"Société Internationale d'Urologie",26,{"id":480,"slug":481,"hasResults":12,"nctId":482,"briefTitle":483,"officialTitle":483,"acronym":484,"eligibilityCriteria":485,"healthyVolunteers":12,"sex":486,"minAge":487,"maxAge":4,"enrollmentInfo":488,"targetDuration":4,"studyType":22,"phases":490,"briefSummary":491,"conditions":492,"keywords":499,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":502,"lastUpdatePostDateStruct":503,"startDateStruct":505,"completionDateStruct":507,"leadSponsor":508,"locationsCount":509},"100625621","ambulatory-long-length-urodynamics-evaluation-100625621","NCT07425015","Ambulatory Long Length URodynamics Evaluation","ALLURE","Inclusion Criteria:\n\n1. Male or female patient must be ≥ 22 years of age.\n2. Patient is a candidate for UDS per standard of care.\n3. Patient is able to provide informed consent.\n\nExclusion Criteria:\n\n1. Patient has one or more symptoms indicative of a urinary tract infection (UTI) (i.e., fever, costovertebral angle pain or tenderness, suprapubic tenderness, worsening urinary frequency, worsening urgency, and\u002For dysuria).\n2. Patient has a history of recurrent UTIs (≥ 3 episodes in previous 12 months).\n3. Patient has used antibiotics within the past 7 days from the baseline\u002Fscreening visit.\n4. Patient diagnosed with neurogenic LUTD (i.e., one or more of these conditions: normal-pressure hydrocephalus, cerebral palsy, spinal cord injuries, traumatic brain injury, stroke, Parkinson's disease, multiple sclerosis, meningomyelocele, spina bifida, dementia, Guillain-Barre syndrome, and tumors involving the central nervous systems or spine).\n5. Patient diagnosed with interstitial cystitis (IC), bladder pain syndrome, painful bladder syndrome or any etiology of chronic pelvic pain syndrome (CPPS).\n6. Patient with a urostomy.\n7. Patient with a colostomy.\n8. Patient has an atypical anatomic structural variation or has had a previous surgical intervention that has permanently changed structural anatomy anywhere along their lower urinary tract (urethra, pelvic floor, urethral sphincter, and\u002For bladder wall) that the principal investigator deems might compromise the placement or retention of the Glean sensors during the study (e.g., strictures).\n9. Patient has a Pelvic Organ Prolapse Quantification (POP-Q) of Grade III or higher (i.e., most distal portion of the prolapse protrudes more than 1 centimeter below the hymen).\n10. Patient with any abnormal or concerning rectal conditions such as ongoing anal fissures, rectocele, fistula, active herpes, or active yeast infections.\n11. Patient has a known inability to void.\n12. Patient has a previous history of radiation leading to bleeding (e.g., hemorrhagic radiation cystitis).\n13. Patient is pregnant (as confirmed by urine pregnancy test or medical history) or breastfeeding, pregnant within the past 6 months, or intending to become pregnant during the study period.\n14. Patients who may not be able to independently use a smart device.\n15. Subjects who, at the principal investigator's determination, would not be appropriate for this study.","ALL","22 Years",{"count":489,"type":21},101,[24],"A prospective, open-label, single arm interventional trial evaluating the safety and performance of the in-clinic and extended monitoring of the lower urinary tract using the Glean Urodynamics System.",[493,494,29,495,496,497,498],"Urology","Urinary Bladder, Overactive","Urodynamics","Home Monitoring","Urinary Incontinence (UI)","Lower Urinary Tract Dysfunction",[500,501,73],"Bright Uro","Glean Urodynamics System","2026-04-13",{"date":504,"type":37},"2026-04-15",{"date":506,"type":37},"2026-02-17",{"date":226,"type":21},{"name":500,"class":44},7,{"id":511,"slug":512,"hasResults":12,"nctId":513,"briefTitle":514,"officialTitle":515,"acronym":516,"eligibilityCriteria":517,"healthyVolunteers":12,"sex":17,"minAge":518,"maxAge":4,"enrollmentInfo":519,"targetDuration":4,"studyType":22,"phases":520,"briefSummary":521,"conditions":522,"keywords":523,"overallStatus":77,"whyStopped":4,"lastUpdateSubmitDate":526,"lastUpdatePostDateStruct":527,"startDateStruct":528,"completionDateStruct":530,"leadSponsor":532,"locationsCount":120},"100633437","concomitant-trans-perineal-prostate-biopsy-and-ablation-bioblation-for-prostate-cancer-100633437","NCT07526675","Concomitant Trans-Perineal Prostate Biopsy and Ablation (Bioblation) for Prostate Cancer","Validation of Concomitant Trans-Perineal Prostate Biopsy and Ablation (Bioblation) for Symptomatic (LUTS) Selected Most Probably Low and Intermediate Risk PCa Patients","Bioblation","Inclusion Criteria:\n\n* Patients with severe Lower Urinary Tract Symptoms (LUTS) meeting the following parameters:\n\n  1. IPSS score \\> 20\n  2. Uroflowmetry flow rate \\\u003C 10 ml\u002Fsec\n  3. Post-void residual \\> 150 cc\n* Patients most probably having low to favorable intermediate-risk prostate cancer, defined as:\n\n  1. PSA level between 4 and 20 ng\u002Fml\n  2. MP-MRI showing 3 or fewer focal lesions\n  3. MP-MRI focal lesions measuring \\\u003C 1.5 cm\n* International or visiting patients requiring early return to their home country due to professional or personal commitments, provided they can undergo short-term management and follow-up coordination\n\nExclusion Criteria:\n\n* Patient PSA level \\> 20 ng\u002Fml\n* More than 3 focal lesions on MP-MRI\n* Metastatic prostate cancer\n* History of lower urinary tract surgery (e.g., TURP, Laser, urinary diversions, artificial urinary sphincter)\n* History of pelvic radiation therapy or radical pelvic surgery","18 Months",{"count":413,"type":21},[24],"This prospective study aims to validate the clinical outcomes of performing a concomitant trans-perineal prostate biopsy and laser ablation (termed \"Bioblation\") during a single session. The intervention is designed for symptomatic patients presenting with lower urinary tract symptoms (LUTS) who are highly suspected to have low to favorable intermediate-risk prostate cancer. By combining diagnosis and targeted treatment under local anesthesia, this approach seeks to facilitate early relief of severe symptoms and a rapid return to daily activities. Ultimately, the study evaluates whether this combined procedure decreases the patient's exposure to multiple, temporally separated interventions without compromising oncological safety or efficacy.",[30,137,29],[30,524,516,525,143,29],"Transperineal Laser Ablation","Focal Therapy","2026-04-09",{"date":502,"type":37},{"date":529,"type":21},"2026-04-10",{"date":531,"type":21},"2026-04-28",{"name":404,"class":86},{"id":534,"slug":535,"hasResults":12,"nctId":536,"briefTitle":537,"officialTitle":537,"acronym":538,"eligibilityCriteria":539,"healthyVolunteers":12,"sex":17,"minAge":96,"maxAge":4,"enrollmentInfo":540,"targetDuration":4,"studyType":22,"phases":541,"briefSummary":542,"conditions":543,"keywords":4,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":544,"lastUpdatePostDateStruct":545,"startDateStruct":546,"completionDateStruct":548,"leadSponsor":550,"locationsCount":120},"100609445","the-edison-system-for-treatment-of-benign-prostatic-hyperplasia-bph-using-histotripsy-100609445","NCT07214675","The Edison System for Treatment of Benign Prostatic Hyperplasia (BPH) Using Histotripsy","WOLVERINE","Inclusion Criteria:\n\n1. Subject is ≥ 50 years of age.\n2. Subject has signed the Ethics Committee (EC) approved trial Informed Consent Form (ICF) prior to any trial related tests\u002Fprocedures and is willing to comply with trial procedures and required follow-up assessments.\n3. Subject is diagnosed with BPH.\n4. Subject has a Body Mass Index (BMI) \\\u003C 27.\n5. Subject has an I-PSS ≥ 15.\n6. Subject has a prostate volume \\> 30 mL and ≤ 150 mL.\n7. Subject has a Qmax ≤ 15 mL\u002Fs with a voided volume of ≥ 125 mL during a uroflow test.\n8. Subject accepts the potential loss of ejaculatory function.\n9. Subject can tolerate general anesthesia. Index-Procedure Imaging Inclusion (Assessed day of procedure)\n10. Subject has an adequate acoustic window to visualize the prostate using the HistoSonics Edison System.\n11. Target treatment volume is ≥ 1 cm from the rectum as visualized on ultrasound, CT or MR imaging.\n\nExclusion Criteria:\n\n1. Subject has a life expectancy of less than one (1) year.\n2. Subject has a known sensitivity to contrast media and cannot be adequately pre-medicated.\n3. Subject has a post-void residual ≥ 150 mL confirmed via ultrasound.\n4. Subject has an estimated glomerular filtration rate (eGFR) ≤ 50 mL\u002Fmin, ≤ 14 days prior to the planned index procedure date.\n5. Subject has uncorrectable coagulopathy.\n6. Subject has an International Normalized Ratio (INR) value ˃ 2.0, ≤14 days prior to the planned index procedure date.\n7. Subject has had a prostatectomy.\n8. Subject has acute prostatitis.\n9. Subject has a diagnosis of or has received treatment for chronic prostatitis or chronic pelvic pain syndrome.\n10. Subject has had a urinary tract infection (UTI) ≤ 3 months prior to the planned index procedure date.\n11. Subject has bladder stones.\n12. Subject is catheter dependent or has a history of intermittent self-catheterization.\n13. Presence of prostatic calcifications in the planned treatment volume (PTV).\n14. Presence of permanent radioactive implants in the rectal wall.\n15. Subject has has a major abdominal or rectal surgery that inhibits visualization of the prostate.\n16. Subject has undergone prior locoregional therapy (e.g., Rezum, laser, Urolift, TURP emboli, or radiation).\n17. Subject has planned locoregional therapy 6 months post index procedure (e.g., Rezum, laser, Urolift, TURP emboli, or radiation).\n18. Subjects who have active cancers (not in remission for the last two years) other than non-melanomatous skin cancers.\n19. Subject is being actively treated in another pharmaceutical or device trial that has not completed its primary endpoint prior to the index procedure or may interfere with the primary outcome measure of this trial.\n20. In the investigator's opinion, histotripsy is not a treatment option for the subject.\n21. Subject has a concurrent condition that could jeopardize the safety of the subject or compliance with the protocol.\n22. Subject's prostate is not treatable by the System's working ranges (refer to User Guide).",{"count":98,"type":21},[24],"The purpose of this trial is to evaluate the safety of histotripsy using the HistoSonics Edison System for treatment of BPH.",[29],"2026-04-08",{"date":526,"type":37},{"date":547,"type":37},"2026-03-20",{"date":549,"type":21},"2027-10",{"name":551,"class":44},"HistoSonics, Inc.",{"id":553,"slug":554,"hasResults":12,"nctId":555,"briefTitle":556,"officialTitle":556,"acronym":557,"eligibilityCriteria":558,"healthyVolunteers":12,"sex":17,"minAge":129,"maxAge":4,"enrollmentInfo":559,"targetDuration":4,"studyType":22,"phases":561,"briefSummary":562,"conditions":563,"keywords":564,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":544,"lastUpdatePostDateStruct":569,"startDateStruct":570,"completionDateStruct":572,"leadSponsor":574,"locationsCount":576},"100483377","comparison-of-functional-outcomes-of-ejaculation-preserving-partial-trans-urethral-resection-of-the-prostate-with-complete-trans-urethral-resection-of-the-prostate-for-benign-prostatic-obstruction-100483377","NCT05574244","Comparison of Functional Outcomes of Ejaculation-preserving Partial Trans Urethral Resection of the Prostate With Complete Trans Urethral Resection of the Prostate for Benign Prostatic Obstruction","PARTURP","Inclusion Criteria:\n\n* Man over 40 years old\n* Indication of surgical management for BPH\n* Prostate volume ≥30 cc and ≤150 cc as evaluated by ultrasonography ( or an MRI if available)\n* IPSS score ≥12\n* Qmax ≤15 ml\u002Fs\n* Affiliated to French national social security system\n* wish and be able to comply with planned visits\n* Able to express his consent\n* Signed informed consent form\n\nExclusion Criteria:\n\n* Unwillingness to accept the treatment\n* No pre-operative ejaculation or sexuality\n* Neurological pathology responsible for micturition disorders\n* History of prostatic surgery\n* Stenosis of the urethra symptomatic\n* History of prostate cancer\n* History of radiotherapy or pelvic surgery\n* Patient refusing the principle of partial surgery\n* Life expectancy \\\u003C3 years\n* Inability to understand the informed consent document, to give consent voluntarily or to complete the study tasks.\n* Participation in another clinical study involving an investigational product within 1 month before study entry.",{"count":560,"type":21},336,[24],"It has been demonstrated that sexual activity was common in the majority of men over 50 years old and was an important component of overall quality of life (QoL). Ejaculatory dysfunction (EjD) is the most common side effect of surgical treatment of benign prostatic obstruction (BPO). It has been considered for decades to be an inevitable consequence of restoring micturition comfort. EjD can have a substantial deleterious effect on the QoL of men with previously maintained regular sexual activity, inducing decreased orgasmic intensity and increased levels of anxiety and depression. A better understanding of the physiology of ejaculation has enabled the emergence of modified surgical techniques that aim to preserve antegrade ejaculation. Our hypothesis is that conservation of ejaculation can be achieved by modified surgical procedures without compromising functional outcomes.",[29],[143,565,566,567,568],"Transurethral resection of prostate","Partial Transurethral resection of prostate","quality of life","Ejaculation",{"date":526,"type":37},{"date":571,"type":37},"2022-09-29",{"date":573,"type":21},"2029-03-31",{"name":575,"class":86},"University Hospital, Bordeaux",17,{"id":578,"slug":579,"hasResults":12,"nctId":580,"briefTitle":581,"officialTitle":582,"acronym":583,"eligibilityCriteria":584,"healthyVolunteers":12,"sex":17,"minAge":4,"maxAge":4,"enrollmentInfo":585,"targetDuration":587,"studyType":57,"phases":4,"briefSummary":588,"conditions":589,"keywords":590,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":595,"lastUpdatePostDateStruct":596,"startDateStruct":598,"completionDateStruct":600,"leadSponsor":602,"locationsCount":604},"100559157","optilume-bph-catheter-system-for-treatment-of-men-experiencing-symptomatic-bph-100559157","NCT06560476","OPtilume™ BPH Catheter SystEm for Treatment of Men eXperiencing Symptomatic BPH","A Prospective Multi-site Registry of Real-world Experience With the OPtilume™ BPH Catheter SystEm for Treatment of Men eXperiencing Symptomatic BPH","APEX","Inclusion Criteria:\n\n1\\. Patients treated with the Optilume BPH Catheter System in accordance with the Instructions for Use (IFU).\n\nExclusion Criteria:\n\n1. Unwilling to abstain from sexual intercourse or use a condom for 30 days post-procedure and utilize a highly effective contraceptive for at least 12 months post-procedure\n2. Presence of an artificial urinary sphincter, penile prosthesis, or stent(s) in the urethra or prostate\n3. Confirmed or suspected malignancy of prostate or bladder.\n4. Active urinary tract infection (UTI)\n5. Anatomy (e.g., presence of false passage or size of meatus) is not suitable for treatment with the Optilume BPH Catheter System",{"count":586,"type":21},500,"2 Years","APEX is a prospective multi-site registry of real-world experience with the Optilume™ BPH Catheter System for treatment of men experiencing symptomatic BPH.",[29],[102,591,592,593,297,594],"Drug Coated Balloon","DCB","Prostate","Optilume","2026-03-23",{"date":597,"type":37},"2026-03-27",{"date":599,"type":37},"2024-03-30",{"date":601,"type":21},"2027-03-30",{"name":603,"class":44},"Urotronic Inc.",9,{"id":606,"slug":607,"hasResults":12,"nctId":608,"briefTitle":609,"officialTitle":609,"acronym":4,"eligibilityCriteria":610,"healthyVolunteers":12,"sex":17,"minAge":54,"maxAge":4,"enrollmentInfo":611,"targetDuration":4,"studyType":22,"phases":613,"briefSummary":614,"conditions":615,"keywords":616,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":623,"lastUpdatePostDateStruct":624,"startDateStruct":625,"completionDateStruct":627,"leadSponsor":629,"locationsCount":631},"100567434","a-prospective-multicenter-open-label-study-of-the-beacon-platform-for-holmium-laser-enucleation-of-the-prostate-holep-100567434","NCT06668142","A Prospective, Multicenter, Open-label Study of the Beacon Platform for Holmium Laser Enucleation of the Prostate (HoLEP)","Inclusion Criteria:\n\n1. Male\n2. Subject has diagnosis of lower urinary tract symptoms and\u002For urinary retention due to benign prostatic enlargement causing bladder outlet obstruction,\n3. Subject is able and willing to comply with all the assessments of the study,\n4. Subject or subject's legal representative has been informed of the nature of the study, agrees to participate, and has signed the informed consent form,\n5. ≥ 45 years of Age,\n6. Prostate volume 40 - 120 cc by transrectal ultrasound (TRUS), magnetic resonance imaging (MRI), or computed tomography (CT), measured within one year prior to procedure,\n7. The subject is indicated for undergoing HoLEP procedure\n\nExclusion Criteria:\n\n1. Urethral stricture, meatal stenosis, or bladder neck contracture - either current or recurrent,\n2. History of prostate cancer or current\u002Fsuspected bladder cancer,\n3. Prostate cancer should be ruled out before participation to the satisfaction of the investigator if Prostate-Specific Antigen (PSA) is above acceptable thresholds,\n4. History of other diseases causing voiding dysfunction including urinary retention (e.g., diagnosis of neurogenic bladder, Parkinson's disease, multiple sclerosis, etc.),\n5. Subjects with overactive bladder in the absence of benign prostatic obstruction as determined by the investigator,\n6. Acute urinary tract infection (UTI) or finding of asymptomatic bacteriuria (Note: subject can be enrolled if the UTI is treated)\n7. Previous pelvic irradiation or radical pelvic surgery,\n8. Previous prostate surgery, including enucleation, resection, vaporization, thermotherapy, ablation, stenting, or prostatic urethral lift,\n9. Inability to stop taking anticoagulants for at least 3 days prior to the procedure or antiplatelets and\u002For coumadin for at least 5 days prior to the procedure (Note: low dose aspirin therapy is permitted),\n10. Any severe illness that would prevent complete study participation or confound study results.\n11. Bleeding tendency disorders,\n12. Future fertility concerns,\n13. Subject has any other disease or condition(s) that would interfere with completion of the study and follow-up assessments, would increase risks of the procedure, or in the judgment of the investigator would potentially interfere with compliance to this study or would adversely affect outcomes,\n14. Concomitant participation in another interventional study",{"count":612,"type":21},54,[24],"Robotic assisted surgery for benign prostatic hyperplasia (BPH)",[29],[71,617,618,102,593,619,620,621,622],"RoLEP","Robotic HoLEP","urology","robotic","Andromeda","ASTRA","2026-03-19",{"date":595,"type":37},{"date":626,"type":37},"2024-12-12",{"date":628,"type":21},"2026-12-30",{"name":630,"class":44},"Andromeda Surgical",3,{"id":633,"slug":634,"hasResults":12,"nctId":635,"briefTitle":636,"officialTitle":637,"acronym":4,"eligibilityCriteria":638,"healthyVolunteers":12,"sex":17,"minAge":96,"maxAge":4,"enrollmentInfo":639,"targetDuration":4,"studyType":22,"phases":641,"briefSummary":642,"conditions":643,"keywords":644,"overallStatus":77,"whyStopped":4,"lastUpdateSubmitDate":647,"lastUpdatePostDateStruct":648,"startDateStruct":650,"completionDateStruct":652,"leadSponsor":654,"locationsCount":120},"100628876","phase-4-silodosin-vs-tamsulosin-for-luts-due-to-bph-a-randomized-crossover-trial-100628876","NCT07467343","Silodosin vs Tamsulosin for LUTS Due to BPH: A Randomized Crossover Trial",": Efficacy of Silodosin Versus Tamsulosin in Patients With Moderate to Severe Lower Urinary Tract Symptoms Due to Benign Prostatic Hyperplasia: A Randomized Crossover Clinical Trial","Inclusion Criteria:\n\n* Male participants aged 50 years or older\n* Diagnosis of benign prostatic hyperplasia with moderate to severe lower urinary tract symptoms\n* International Prostate Symptom Score of 8 or greater\n* Prostate volume of 30 mL or greater\n* Able and willing to provide informed consent\n* No active treatment for benign prostatic hyperplasia during the month before enrollment\n\nExclusion Criteria:\n\n* Suspected neurogenic bladder\n* Bladder neck contracture\n* Urethral stricture\n* Chronic urinary retention\n* Prostate cancer\n* Urinary bladder stones\n* Urinary bladder tumors\n* History of prostate surgery\n* Known allergy, hypersensitivity, or contraindication to silodosin or tamsulosin\n* Current use of alpha-adrenergic blocker therapy\n* Severe renal impairment with creatinine clearance less than 30 mL\u002Fmin\n* Severe hepatic impairment\n* Concomitant use of strong cytochrome P450 3A4 inhibitors, including ketoconazole, clarithromycin, itraconazole, or ritonavir",{"count":640,"type":21},140,[189],"The goal of this randomized crossover clinical trial is to compare the efficacy and safety of Silodosin versus Tamsulosin in patients with moderate to severe lower urinary tract symptoms due to Benign Prostatic Hyperplasia. The main questions it aims to answer are:\n\nDoes Silodosin provide superior improvement in symptom scores (IPSS) compared to Tamsulosin?\n\nIs there a difference in safety profile and adverse events between the two treatments?\n\nResearchers will compare both treatments in a crossover design, where each participant receives both medications in different periods without a washout phase, to evaluate individual response differences.\n\nParticipants will:\n\nReceive both study medications in different periods according to random allocation.\n\nUndergo periodic assessment of urinary symptoms and quality of life.\n\nPerform routine follow-up evaluations including symptom scoring and urine flow measurements.",[29,143],[220,196,645,29,143,347,73,646],"Alpha-1 Adrenergic Antagonists","Postvoid Residual Urine","2026-03-12",{"date":649,"type":37},"2026-03-16",{"date":651,"type":21},"2026-03-22",{"date":653,"type":21},"2026-10-22",{"name":655,"class":86},"Ain Shams University"]